中国中药控股有限公司(00570) 7月17日公告，根据未经审计的综合管理账目初步评估，预计截至2026年6月30日止六个月将录得净亏损约8亿元至8.5亿元；上年同期亏损约1.42亿元。\n\n公司表示，业绩下滑主要受以下因素影响：一是中药配方颗粒业务因行业政策调整及市场环境变化导致销售收入和盈利能力下降，并产生进一步的商誉减值；二是中成药业务及中药材生产经营业务收入规模和盈利能力下降；三是期内资产减值、信用减值及部分附属公司补缴税款增加。\n\n公告称，上述商誉减值为非现金性质。公司将通过提升运营效率、优化资源配置及改革营销模式等方式，应对行业竞争及宏观经济环境带来的挑战。\n\n公司计划于2026年8月底前披露截至2026年6月30日止六个月的中期业绩。公司提醒股东及潜在投资者在买卖公司股份时保持审慎。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.